Von Willebrand Therapies Market Size, Share & Industry Analysis, Analysis, By Disease Type (VWD 1, VWD 2, and VWD 3), By Therapy Type (Desmopressin, Plasma-Derived VWF Concentrates, Recombinant VWF Concentrate, and Others), By Route of Administration (Intranasal, Intravenous, and Others), By Distribution Channel (Hospital Pharmacy & Retail Pharmacy, Specialty Pharmacy, and Others), and Regional Forecast, 2026-2034

Von Willebrand Disease (VWD) is a common, inherited bleeding disorder where the blood lacks sufficient von Willebrand factor (VWF), a protein essential for blood clotting, or the existing VWF doesn't function properly. This leads to easy bruising, prolonged bleeding from minor injuries or procedures, heavy menstrual bleeding, and nosebleeds. Factor VIII is administered as a replacement therapy for the disease.

The global von Willebrand disease (vWD) therapies market is expanding steadily, driven by increasing awareness, better diagnostic capabilities, and broader treatment availability. The growth of the market is fuelled by the rising adoption of recombinant von Willebrand factor products to reduce risks linked to plasma-derived therapies. Supportive government initiatives, patient-assistance programs, and reimbursement policies are further expected to enhance access to these advanced treatments and support the market expansion. Additionally, strategic partnerships, collaborations, mergers, and acquisitions, along with hefty investment in research and development and novel biologics, subsequently followed by approval by regulatory bodies, are expected to create strong future opportunities for the market.

• For instance, in May 2023, Vega Therapeutics, Inc. received orphan drug designation for VGA039 from the U.S. FDA for the treatment of the rare bleeding disorder, von Willebrand disease (VWD).

Von Willebrand Therapies Driver

High Presence of Von Willebrand Disease Allele in Population to Pose a Risk of Increasing Prevalence and Boost Therapeutic Demand

The high prevalence of von Willebrand disease (vWD) alleles in the general population increases the likelihood of both symptomatic and undiagnosed cases, thereby posing a growing public health concern. Since vWD is often underdiagnosed, improved awareness and genetic screening are expected to reveal a larger patient pool over time. This expanding diagnosis base will directly fuel the demand for therapeutic interventions, especially advanced recombinant and long-acting therapies. As a result, the genetic predisposition of populations serves as a significant driver for sustained growth in the global vWD therapies market.

• For instance, in October 2023, npj Genomic Medicine published an article titled “Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases” that reported analysis of 141,456 individuals. According to the study, there were 31,785 alleles with VWF variants predicted or known to be pathogenic. They estimated the global prevalence for dominant forms of VWD (type 1, 2A, 2B, 2M) as approximately 74 per 1000 individuals for type 1, and lower but non-negligible values for other types. This indicates that many people carry variants that could lead to VWD, many of whom may be undiagnosed. Such a high presence of the disease allele to heighten the demand for therapeutics in the market in the upcoming years, driving growth.

Commonly Reported Bleeding Symptoms Among Women with Von Willebrand Disease

In May 2024, the CDC reported a common bleeding symptom among women with von Willebrand disease based on a study of 102 women.

Von Willebrand Therapies Restraint

Underdiagnoses or Misdiagnoses to Undermine the Demand and Hamper Market Growth

One of the key restraints in the von Willebrand disease (vWD) therapies market is the underdiagnosis and misdiagnosis of the disease, particularly in mild cases. Since symptoms can overlap with other bleeding disorders or remain unnoticed until surgery or trauma, many patients go untreated, which limits the overall addressable market. Additionally, the high cost of recombinant therapies and limited availability of plasma-derived products in low- and middle-income countries restrict widespread adoption. Supply chain challenges for plasma-based products, stringent regulatory requirements, and reimbursement gaps in some regions also act as barriers to market expansion. 

• For instance, in August 2021, NIH published a report titled ‘Why is Misdiagnosis of von Willebrand Disease Still Prevalent and How Can We Overcome It? The report highlighted how the disease experiences significant diagnostic dilemmas and inaccuracies, and in turn leads to significant avoidable patient harm, including inappropriate testing, overdiagnosis, underdiagnosis, and inadequate treatment.

Von Willebrand Therapies Opportunity

Increasing Research & Development for Pipeline Development Creates Indispensable Market Growth Avenues

Increasing research and development (R&D) efforts in von Willebrand disease (vWD) are opening indispensable growth avenues for the market. Pharmaceutical companies and academic institutes are investing in next-generation recombinant factors, gene therapy, and long-acting biologics to address unmet needs beyond plasma-derived treatments. These innovations aim to reduce treatment frequency, improve safety, and enhance patient quality of life, thereby attracting greater adoption. The rising number of clinical trials and regulatory fast-tracks reflects strong pipeline momentum and investor interest. As these advanced therapies progress toward approval, they are expected to expand the market landscape and patient access significantly.

• For instance, in February 2025, Hemab Therapeutics initiated its Phase1/2 clinical study trial for investigating HMB-002, a potential first-in-class subcutaneous therapy for VWD. The therapeutic candidate HMB-002 is the first fixed-dose subcutaneously administered antibody-based preventative therapy aiming to increase levels of von Willebrand Factor (VWF) and Factor VIII and promote sustained hemostatic correction.

Key Insights

The report covers the following key insights:

• Prevalence of von Willebrand Disease, By Key Countries/ Regions
• Regulatory Scenarios, By Key Countries/Regions
• Pipeline Analysis, By Key Companies
• Key Industry Developments - Mergers, Acquisitions & Partnerships

Segmentation

Analysis by Disease Type

On the basis of product type, the global von Willebrand Therapies is segmented into VWD1, VWD2, and VWD3. Among these, the VWD 1 segment is expected to account for a significant segmental share. The high share is attributed to VWD 1 due to high prevalence. Although type 1 is milder in nature, due to high patient volumes is expected to dominate the market. 

Moreover, key companies are focusing on new product launches, FDA clearances, upgrades, of software positioning it as a leading segment. 

• For instance, in October 2023, NIH published a study titled ‘Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centers in the U.S.’ The report conducted a study of 24,238 patients with a diagnosis of VWD who attended HTCs. Age-adjusted HTC-treated prevalence was 7.2/100,000 for Type 1, 1.2/100,000 for Type 2, and 1.7/million for Type 3.

Analysis by Therapy Type

On the basis of therapy type, the market is divided into desmopressin, plasma-derived VWF concentrates, recombinant VWF concentrate, and others.

The recombinant VWF concentrate segment is projected to have a strong foothold on the global market. The high segmental share is due to the higher safety profile and lower adverse allergic reactions to recombinant VWF concentrate.

• For instance, in June 2025, Hemab Therapeutics showcased positive clinical and preclinical data across the bleeding disorder pipeline at ISTH 2025 Congress. HMB-002 clinical proof-of-mechanism data in Von Willebrand disease support its potential as a first-in-class prophylactic therapy by elevating VWF levels and extending half-life. Such developments are expected to boost the segment growth in the market. 

Analysis by Route of Administration

On the basis of route of administration, the market is segmented into intranasal, intravenous, and subcutaneous. Among these intravenous segment is expected to generate a significant revenue share in the global von Willebrand therapies market. The intravenous route of administration exhibits various advantages over other such as precise delivery, rapid onset of action, and higher bioavailability. Due to these advantages, the segment is expected to grow. This has led to greater adoption of these intravenously administered VWD factors, followed by regulatory approval.

• For instance, in September 2025, Takeda Pharmaceutical Company Limited received a supplemental Biologics License Application (sBLA) from the U.S. FDA for VONVENDI [Recombinant von Willebrand factor], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 diseases.

Analysis by Age Group

In terms of age group, the global market is segmented into pediatric and adult. The pediatric segment is expected to generate more demand and boost the market growth. The high segmental share is attributed to the increasing number of awareness programs by the key players to boost the adoption of these products in pediatric patients, as they are more prone to these blood disorders.

• For instance, in February 2024, Octapharma AG launched an expanded and improved website as a global initiative aimed at increasing awareness of von Willebrand disease (VWD). The development is central to the company’s commitment to increasing awareness. 

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacy & retail pharmacy, specialty pharmacy, and others.

The hospital pharmacy & retail pharmacy segment is expected to hold a significant share in the global von Willebrand therapies market. These locations are projected to account for a high segmental share as hospitals are the first point of contact for blood disorders. Additionally, specialized storage, handling requirements, and immediate availability in acute care settings make hospital pharmacies the primary hub for dispensing these therapies. 

• For example, the Hemophilia Foundation of Michigan reported that HRSA funded a network of more than 135 Hemophilia Treatment Centers (HTCs) to provide integrated services to and increased access to care for children and adults with rare, inherited bleeding disorders. These HTCs currently provide services to over 30,000 individuals affected by hemophilia, von Willebrand disease (VWD), and other rare coagulation disorders.
• Similarly, in October 2023, the National Bleeding Disorders Foundation collaborated with partners in the U.S. and around the world to treat people with bleeding disorders and ensure worldwide access to treatment and care—such collaborations to drive the segmental growth.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global von Willebrand Therapies in 2024. The region is expected to dominate due to its high disease awareness and advanced diagnostic infrastructure, ensuring higher diagnosis. The region benefits from strong regulatory approvals, such as the FDA’s expanded indication for recombinant VWF, widening treatment access. Robust healthcare spending, favorable reimbursement policies further support the adoption of high-cost recombinant therapies, along with increasing prevalence, augmenting demand.

• For instance, in May 2024, the U.S. Centers for Disease Control and Prevention reported that the disease affects upto 1.0% of the total population of the U.S. Between 2012 and 2023, more than 33,456 men, women, and children were seen at hemophilia treatment centers for treatment of VWD.

Europe is expected to grow with a significant market share in the forecasted period. Europe maintains a strong market position, supported by well-established healthcare systems and centralized rare disease networks that ensure timely diagnosis and management of von Willebrand disease. The region benefits from regulatory support through the EMA and widespread adoption of advanced recombinant therapies. Strong government reimbursement policies and patient assistance programs make high-cost therapies more accessible. Furthermore, high awareness among clinicians and patients drives demand for preventive and specialized care. 

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The high growth rate is attributed to rising healthcare expenditure and rapid expansion of healthcare infrastructure across emerging economies such as India and China. Increasing disease awareness, diagnostic, and government-led rare disease programs are helping improve early diagnosis rates. The region is also witnessing a growing patient pool due to rising prevalence and improvement in diagnostics. 

Additionally, increasing availability of recombinant and plasma-derived therapies through collaborations and partnerships is boosting market penetration. Growing interest from multinational players investing in clinical trials and market entry strategies further strengthens the Asia Pacific’s growth trajectory.

• For instance, in June 2024, the National Blood Authority, Australia, reported that there were 2,797 patients with von Willebrand disease in Australia in 2024. Such high patient volumes to driving the growth in the region.

Key Players covered

The global von Willebrand Therapies is consolidated, with a few players capturing a major market player. The report includes the profiles of the following key players.

• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)
• STAR Therapeutics Inc. (U.S.)
• Hemab Therapeutics (Denmark)
• Vega Therapeutics, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Sanofi (France)

Key Industry Developments

• In January 2025, Star Therapeutics Inc. received Fast Track designation from the U.S. FDA for VGA039 in von Willebrand disease (VWD). VGA039 is an investigational monoclonal antibody targeting Protein S to restore balance in blood clotting.
• In June 2024, Star Therapeutics presented clinical data from VIVID 1 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 clinical study of VGA039 in healthy volunteers. VGA039 is designed as a universal hemostatic therapy for numerous bleeding disorders and potentially the first subcutaneous therapy for von Willebrand disease (VWD).
• In April 2024, Octapharma AG received orphan drug exclusivity from the U.S FDA for Wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human) L for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older with von Willebrand disease (VWD).